
Opinion|Videos|September 10, 2024
Case Study: Diagnosing and Managing BPH in a Male Patient With Urinary Symptoms
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Patient Case Example: A man in his late 60s who presents with the following:
- History of straining to initiate and maintain a urinary stream, a weak and intermittent urinary stream, a sensation of incomplete bladder emptying after urination, and nocturia; absence of hematuria or dysuria.
- Past Medical History:
- No history of urinary tract infections or other urological conditions
- Hypertension (well-controlled with medication)
- Hyperlipidemia
- No previous surgical history
- Physical Examination:
- Digital rectal examination reveals an enlarged, nonnodular prostate (approximately 50 g); no other significant findings.
- Laboratory and Diagnostic Tests: Serum prostate-specific antigen level: 2.5 ng/mL; urinalysis: normal; uroflowmetry: peak flow rate of 8 mL/sec (borderline obstructed); post-void residual urine volume: 120 mL; transrectal ultrasound: prostate volume estimated at 55 g.
- Please describe your approach to diagnosing, treating, and managing this patient.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5














